中文
  • About Us
    Corporate Overview Management Team Board of Directors Contact Us
  • Our Focus
    NASH Viral Hepatitis HIV/AIDS
  • Pipeline & Products
    Pipeline Products Clinical Trials
  • Partnership
  • Investors
    Financials & Filing Presentation Materials
  • News
  • Careers
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • ASC40 (TVB-2640) Phase 2 NASH Trial Completed Patient Enrollment in China

    2020-11-19

  • Change in Use of Proceeds From the Global Offering for Expansion of R&D Portfolio into Hepatitis B Clinical Cure and NASH

    2020-11-18

  • Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42,an FXR Agonist

    2020-10-12

  • Ascletis’ Strategic Partner Sagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640(ASC40) in NASH at AASLD’s The Liver Meeting Digital Experience™ 2020

    2020-10-10

  • Gannex Filed US IND for Its NASH Drug ASC42, an FXR Agonist

    2020-09-14

  • «
  •  
  • 1
  • 2
  • 3
  • 4
  •  
  • »
    • © 2018 Ascletis Pharma Inc.
    • 浙公网安备 33010802003344号
    • All Rights Reserved
    • 浙ICP备 11050387号

    contact

    • pr@ascletis.com
    • bd@ascletis.com
    • hr@ascletis.com
    • clinicaltrials@ascletis.com

    © 2018 Ascletis Pharma Inc. All Rights Reserved
    浙公网安备 33010802003344号 浙ICP备 11050387号